行情

PTLA

PTLA

Portola Pharma
NASDAQ

实时行情|Nasdaq Last Sale

13.51
+0.04
+0.30%
盘后: 13.51 0 0.00% 16:50 02/21 EST
开盘
13.45
昨收
13.47
最高
13.54
最低
13.20
成交量
122.79万
成交额
--
52周最高
37.95
52周最低
12.62
市值
10.51亿
市盈率(TTM)
-3.2568
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTLA价格均价为23.33,最高价位35.00,最低价为17.00。

EPS

PTLA 新闻

更多
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FSCT, PTLA, TCNNF INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
  • GlobeNewswire · 1天前
  • ROSEN, NATIONAL TRIAL LAWYERS, Reminds Portola Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – PTLA
  • GlobeNewswire · 2天前
  • The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FSCT, OPRA and PTLA
  • ACCESSWIRE · 3天前
  • PTLA DEADLINE: Pawar Law Group Reminds Investors of March 16 Deadline in Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc. PTLA
  • GlobeNewswire · 3天前

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

PTLA 简况

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
展开

微牛提供Portola Pharmaceuticals Inc(NASDAQ-PTLA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTLA股票新闻,以帮助您做出投资决策。